Role of Genetics
Meet Levi, age 10. Amenable to exon 45 skipping

The genetic mutation behind Duchenne.

Understanding the cause of Duchenne begins with understanding the role of proteins and genes in how our bodies function.


Proteins are necessary for many important functions in the body, such as digesting our food, growing our bones, or—in the case of the protein called dystrophin—helping our muscles work properly.

Genes are made up of segments, called “exons,” that tell our cells which proteins to make. The dystrophin gene is made up of 79 exons that, when linked together, form the instructions for making dystrophin.

Image
Meet Levi, age 10. Amenable to exon 45 skipping

Meet Levi, age 10
Amenable to exon 45 skipping

Graphic of dystrophin gene – saying 'we're exons!'


What is a genetic mutation?

A mutation is a change in a person's DNA. Mutations range in size from a small (a single rung on a ladder) to a large segment of DNA. Every mutation causes a different effect on our bodies. A mutation on the dystrophin gene means dystrophin is not produced—resulting in Duchenne.

3 common types of mutations.

Large deletions

One or more exons are missing

72%

of people with Duchenne 
 

Large duplications

One or more exons are duplicated

7%

of people with Duchenne 
 

Other changes

Small deletions or interruptions in the instructions

20%

of people with Duchenne 
 

9%

About 9% of people diagnosed with Duchenne have a genetic mutation that is amenable to AMONDYS 45. Learn what this means.

AMONDYS 45 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the dystrophin gene that can be treated by skipping exon 45. The indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

The importance of genetic testing.

While there is presently no cure for Duchenne, advances in research are ongoing. Genetic testing can now pinpoint the specific exons that are missing from the dystrophin gene. That’s why it’s so important for every child living with Duchenne to have a current genetic test—and for parents to understand the results.
 

If your child has a confirmed diagnosis of Duchenne, have they had a genetic test?
 

No.

 

 

 

doctor icon

Now is the time to talk to your child's doctor about testing.
Learn about genetic testing.

 

Yes,

a recent test, but I‘m not sure about the results.

 

results icon


Ask your child’s doctor to review the test to see if the genetic mutation is identified. Learn how to read the test results yourself.

Yes,

but it was several years ago.

 

 

dna icon


Test methods have improved in recent years. Talk to your doctor about a retest to identify the mutation.

4 reasons to get a genetic test.

How is a genetic test performed? Getting a genetic test usually involves providing a blood or saliva sample.

1.

To confirm a Duchenne diagnosis

2.

To identify the genetic mutation and explore possible therapy options

3.

To facilitate potential clinical trial participation

4.

To assist with family planning

Wondering what
to expect?

Get insights into the Duchenne diagnostic process.


 

Insights into the Duchenne diagnostic process – Noticing symptoms – Initial diagnosis – Confirmed diagnosis

Ready to talk to your child’s doctor?

Explore our Doctor Discussion Guide.

chat icon
Image
Desktop star

Sign up to get updates
from Sarepta.  

Related FAQs

How will I know if my child can be treated with AMONDYS 45?

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

Is the treatment effective?

Weekly infusions of AMONDYS 45 helped the body make a shorter form of the dystrophin protein.a View the results from an ongoing clinical study.
 

AMONDYS 45 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 45.


This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.


aBoys treated with AMONDYS 45 showed varying levels of increased dystrophin production after 48 weeks. In an ongoing clinical study, 27 boys (median age 9 years) receiving AMONDYS 45 had an average dystrophin level of 1.74% of normal, compared to 0.76% in 16 boys who received a placebo infusion.

Read More

 

What is AMONDYS 45 (casimersen)?

AMONDYS 45 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the dystrophin gene that can be treated by skipping exon 45.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT SAFETY INFORMATION

Contraindications: Do not receive AMONDYS 45 if you are allergic to casimersen or any of the ingredients in AMONDYS 45. Serious allergic reactions to casimersen have included anaphylaxis, which may include difficulty breathing, tightness in the chest, and angioedema which may include swelling of the mouth, face, lips, or tongue.

Hypersensitivity Reactions: Serious allergic reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with AMONDYS 45. Patients should seek immediate medical care should they experience signs and symptoms of allergic reactions. Your doctor will institute appropriate medical treatment which may include slowing, interrupting, or discontinuing the AMONDYS 45 infusion. Your doctor will monitor you until the condition resolves.

Kidney Toxicity and Monitoring: Damage to the kidneys was seen in animals who received casimersen. Although damage to the kidneys was not seen in clinical studies with AMONDYS 45, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

Adverse Reactions: Side effects occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in patients who received an inactive intravenous (IV) infusion were (AMONDYS 45, placebo): upper respiratory tract infection (65%, 55%), cough (33%, 26%), fever (33%, 23%), headache (32%, 19%), joint pain (21%, 10%), and pain in mouth and throat (21%, 7%).

Other side effects that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than patients who received an inactive IV infusion were: ear pain, nausea, ear infection, pain after injury, and dizziness and light-headedness.

What do I do if I have side effects?

Ask your healthcare provider for advice about any side effects that concern you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

The information provided here does not include all that is known about AMONDYS 45. To learn more, talk with your healthcare provider.

Before receiving this infusion, please see the full Prescribing Information for AMONDYS 45 (casimersen).